LBA65 First-line nivolumab (NIVO) plus ...
Type de document :
Compte-rendu et recension critique d'ouvrage
Titre :
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
Auteur(s) :
Peters, S. [Auteur]
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] [CHUV]
Scherpereel, A. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Cornelissen, R. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Oulkhouir, Y. [Auteur]
Hôpital Côte de Nacre [CHU Caen]
Greillier, L. [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
Kaplan, M.A. [Auteur]
Talbot, T. [Auteur]
Monnet, I. [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Hiret, S. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
CRLCC René Gauducheau
Baas, P. [Auteur]
Leiden University Medical Center [LUMC]
Nowak, A.K. [Auteur]
The University of Western Australia [UWA]
Fujimoto, N. [Auteur]
Tsao, A.S. [Auteur]
MD Anderson Cancer Center [Houston]
Mansfield, A.S. [Auteur]
Mayo Clinic [Rochester]
Popat, S. [Auteur]
Zhang, X. [Auteur]
Bristol-Myers Squibb [Princeton]
Hu, N. [Auteur]
Bristol-Myers Squibb [Princeton]
Balli, D. [Auteur]
Bristol-Myers Squibb [Princeton]
Sanzari, J. [Auteur]
Bristol-Myers Squibb [Princeton]
Zalcman, G. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] [CHUV]
Scherpereel, A. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Cornelissen, R. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Oulkhouir, Y. [Auteur]
Hôpital Côte de Nacre [CHU Caen]
Greillier, L. [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
Kaplan, M.A. [Auteur]
Talbot, T. [Auteur]
Monnet, I. [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Hiret, S. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
CRLCC René Gauducheau
Baas, P. [Auteur]
Leiden University Medical Center [LUMC]
Nowak, A.K. [Auteur]
The University of Western Australia [UWA]
Fujimoto, N. [Auteur]
Tsao, A.S. [Auteur]
MD Anderson Cancer Center [Houston]
Mansfield, A.S. [Auteur]
Mayo Clinic [Rochester]
Popat, S. [Auteur]
Zhang, X. [Auteur]
Bristol-Myers Squibb [Princeton]
Hu, N. [Auteur]
Bristol-Myers Squibb [Princeton]
Balli, D. [Auteur]
Bristol-Myers Squibb [Princeton]
Sanzari, J. [Auteur]
Bristol-Myers Squibb [Princeton]
Zalcman, G. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Titre de la revue :
Annals of Oncology
Pagination :
S1341-S1342
Éditeur :
Elsevier
Date de publication :
2021-09
ISSN :
0923-7534
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Résumé en anglais : [en]
BackgroundIn the randomized phase 3 CheckMate 743 study (NCT02899299), NIVO + IPI significantly prolonged overall survival (OS) vs chemo in pts with unresectable MPM. Here we report updated efficacy and safety with a 3-y ...
Lire la suite >BackgroundIn the randomized phase 3 CheckMate 743 study (NCT02899299), NIVO + IPI significantly prolonged overall survival (OS) vs chemo in pts with unresectable MPM. Here we report updated efficacy and safety with a 3-y minimum follow-up (f/u), as well as novel biomarker analyses.MethodsPts with untreated MPM, stratified by histology (epithelioid vs non-epithelioid) and sex, were randomized 1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W (≤ 2 y) or to chemo Q3W (6 cycles). The primary endpoint was OS; safety and biomarker assessments were prespecified exploratory endpoints. OS association with a 4-gene inflammatory gene expression signature (CD8A, PD-L1, STAT-1, LAG-3) was estimated by RNA sequencing and categorized as high vs low relative to median score. Lung immune prognostic index (LIPI) score was based on baseline (BL) derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels.ResultsWith a minimum f/u of 35.5 mo (database lock [DBL] 7 May 2021), NIVO + IPI continued to provide OS benefit vs chemo (HR 0.75, 95% CI 0.63–0.90; Table). In exploratory biomarker analyses, median OS was longer for pts with high vs low inflammatory gene signature score (21.8 vs 16.8 mo) in the NIVO + IPI arm; this signature score was not associated with prolonged OS for chemo. OS showed a trend favoring NIVO + IPI vs chemo across good, intermediate, and poor BL LIPI subgroups; HR (95% CI), 0.78 (0.60–1.01), 0.76 (0.57–1.01), and 0.83 (0.44–1.57), respectively. Grade 3–4 treatment-related adverse events occurred in 30.7% (NIVO + IPI) and 32.0% (chemo) of pts; no increase was reported from the previous DBL. Table: LBA65Efficacy outcomes with NIVO + IPI vs chemoNIVO + IPI (n = 303) Chemo (n = 302)OS Median (95% CI), mo 18.1 (16.8–21.0) 14.1 (12.4–16.3)HR vs chemo (95% CI) 0.75 (0.63–0.90) —3-y OS rate (95% CI), % 23.2 (18.4–28.2) 15.4 (11.5–19.9)3-y PFS a rate (95% CI), % 13.6 (9.4–18.6) 0.8 (0.1–3.9)ORR a (95% CI), % 39.6 (34.1–45.4) 44.0 (38.4–49.8)DOR a,b Median (95% CI), mo 11.6 (8.2–16.8) 6.7 (5.6–7.1)3-y DOR rate, % 28 0aPer blinded independent central review; bCalculated in patients with a response (NIVO + IPI, n = 120; chemo, n = 133). DOR, duration of response; ORR, objective response rate; PFS, progression-free survival.ConclusionsWith a 3-y minimum f/u, NIVO + IPI continued to provide survival benefit vs chemo in pts with unresectable MPM despite pts being off therapy for 1 y; no new safety signals were observed. Exploratory analyses suggest that a high inflammatory gene signature score may correlate with improved survival benefit with NIVO + IPI.Lire moins >
Lire la suite >BackgroundIn the randomized phase 3 CheckMate 743 study (NCT02899299), NIVO + IPI significantly prolonged overall survival (OS) vs chemo in pts with unresectable MPM. Here we report updated efficacy and safety with a 3-y minimum follow-up (f/u), as well as novel biomarker analyses.MethodsPts with untreated MPM, stratified by histology (epithelioid vs non-epithelioid) and sex, were randomized 1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W (≤ 2 y) or to chemo Q3W (6 cycles). The primary endpoint was OS; safety and biomarker assessments were prespecified exploratory endpoints. OS association with a 4-gene inflammatory gene expression signature (CD8A, PD-L1, STAT-1, LAG-3) was estimated by RNA sequencing and categorized as high vs low relative to median score. Lung immune prognostic index (LIPI) score was based on baseline (BL) derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels.ResultsWith a minimum f/u of 35.5 mo (database lock [DBL] 7 May 2021), NIVO + IPI continued to provide OS benefit vs chemo (HR 0.75, 95% CI 0.63–0.90; Table). In exploratory biomarker analyses, median OS was longer for pts with high vs low inflammatory gene signature score (21.8 vs 16.8 mo) in the NIVO + IPI arm; this signature score was not associated with prolonged OS for chemo. OS showed a trend favoring NIVO + IPI vs chemo across good, intermediate, and poor BL LIPI subgroups; HR (95% CI), 0.78 (0.60–1.01), 0.76 (0.57–1.01), and 0.83 (0.44–1.57), respectively. Grade 3–4 treatment-related adverse events occurred in 30.7% (NIVO + IPI) and 32.0% (chemo) of pts; no increase was reported from the previous DBL. Table: LBA65Efficacy outcomes with NIVO + IPI vs chemoNIVO + IPI (n = 303) Chemo (n = 302)OS Median (95% CI), mo 18.1 (16.8–21.0) 14.1 (12.4–16.3)HR vs chemo (95% CI) 0.75 (0.63–0.90) —3-y OS rate (95% CI), % 23.2 (18.4–28.2) 15.4 (11.5–19.9)3-y PFS a rate (95% CI), % 13.6 (9.4–18.6) 0.8 (0.1–3.9)ORR a (95% CI), % 39.6 (34.1–45.4) 44.0 (38.4–49.8)DOR a,b Median (95% CI), mo 11.6 (8.2–16.8) 6.7 (5.6–7.1)3-y DOR rate, % 28 0aPer blinded independent central review; bCalculated in patients with a response (NIVO + IPI, n = 120; chemo, n = 133). DOR, duration of response; ORR, objective response rate; PFS, progression-free survival.ConclusionsWith a 3-y minimum f/u, NIVO + IPI continued to provide survival benefit vs chemo in pts with unresectable MPM despite pts being off therapy for 1 y; no new safety signals were observed. Exploratory analyses suggest that a high inflammatory gene signature score may correlate with improved survival benefit with NIVO + IPI.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :